Jasper Therapeutics, Inc.

Jasper Therapeutics, Inc. traces its public-market origins to Amplitude Healthcare Acquisition Corporation, a blank-check company that traded on Nasdaq under the ticker AMHC and completed its initial public offering in 2021, with Amplitude Healthcare Sponsor, LLC serving as the sponsoring entity. The SPAC targeted the healthcare and biopharmaceutical sector, ultimately completing its business combination with Jasper Therapeutics — a clinical-stage company developing therapies centered on hematopoietic stem cell conditioning and mast cell diseases — with the de-SPAC transaction closing in March 2022. Following the merger, the combined company has continued operating and filing periodic disclosures, including the Form 8-K filed with the SEC on June 12, 2024. Visit SpacDesk and sign up for full data, filings history, and deal analytics on Jasper Therapeutics and hundreds of other SPAC transactions.